Document is current
Any future updates will be listed below
-
Authors
Qu, Xiaoyan https://orcid.org/0000-0003-0863-5417
An, Gang
Sui, Weiwei
Wang, Tingyu
Zhang, Xian
Yang, Junfang
Zhang, Yan
Zhang, Lu
Zhu, Dan
Huang, Jiaqi
Zhu, Shigui
Yao, Xin
Li, Jing
Zheng, Chengxiao
Zhu, Kevin
Wei, Yutian
Lv, Xiaoteng
Lan, Liping
Yao, Yihong
Zhou, Daobin
Lu, Peihua
Qiu, Lugui
Li, Jianyong
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03815383 at ClinicalTrials.govnct03751293 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
https://doi.org/10.1136/jitc-2022-005145
nct04295018 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
https://doi.org/10.1136/jitc-2022-005145
nct04322292 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
https://doi.org/10.1136/jitc-2022-005145
Documents that mention this clinical trial
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
https://doi.org/10.1136/jitc-2022-005145
- License Information
